MilliporeSigma has expanded its end-to-end biodevelopment centers to meet increasing customer demand for its turnkey portfolio of bioprocessing products, manufacturing capabilities and technological expertise.

The expansion, which includes the opening of two new process development centers in the U.S. and China, follows the commercial success of MilliporeSigma’s biodevelopment center in Martillac, France. The two new units will be located in close proximity to customers in the Shanghai and Boston metropolitan areas. Each will provide a full range of process development capabilities and services. This includes cell line development services, both upstream and downstream process development, as well as non-GMP clinical production.

“We are seeing an increasing global demand for end-to-end process development solutions and MilliporeSigma offers a one-stop shop for biopharma customers,” said Udit Batra, member of the executive board, Merck KGaA, and chief executive officer, MilliporeSigma. “This expansion reinforces our position as the premier supplier of all process development and clinical stage manufacturing solutions, materials and services needed for the production of biologics. This is a strategic, high-potential investment for MilliporeSigma specifically designed to meet customer needs on three continents.”

MilliporeSigma’s biodevelopment center in Martillac, France, is a fully operational single-use, GMP facility for manufacturing clinical stage batches. Equipped with a full suite of MilliporeSigma technologies, including the 2000-liter single-use Mobius bioreactor, Martillac offers biopharma companies a complete solution to support their clinical development programs.

In addition to the Mobius bioreactor, the end-to-end portfolio includes solutions such as Lynx CDR, Viresolve Process Area Modules, Pelliconand Centinel Intelligence Virus Defense.